查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1916943

放射性核種藥物偶聯物市場按釋放類型、標靶分子、適應症、通路和最終用戶分類－2026-2032年全球預測

Radionuclide Drug Conjugate Market by Emission Type, Targeting Molecule, Indication, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年放射性核種藥物複合物市值為 8.4027 億美元，預計到 2026 年將成長至 9.0601 億美元，年複合成長率為 10.77%，到 2032 年將達到 17.2027 億美元。

關鍵市場統計數據
基準年 2025 8.4027億美元
預計年份：2026年 9.0601億美元
預測年份 2032 1,720,270,000 美元
複合年成長率 (%) 10.77%

本書權威地介紹了放射性核種藥物偶聯物，闡述了其科學原理、臨床應用前景以及構成當前策略的操作前提。

放射性核種藥物偶聯物融合了標靶分子治療和放射性有效載荷遞送技術，旨在選擇性地將細胞毒性輻射遞送至惡性組織，同時保護健康組織。這些藥物將標靶配體與放射性同位素結合，使臨床醫生能夠利用分子辨識技術定位治療性輻射，某些偶聯物也具備診斷影像功能，可作為治療性診斷策略的一部分。這種雙重效用有助於最佳化患者選擇和治療監測，進一步激發了臨床和商業性對這些治療方法的興趣。

技術突破、臨床檢驗和不斷發展的護理模式如何重塑放射性藥物治療的競爭格局和運作模式

放射性核種藥物偶聯物領域正經歷著變革性的轉變，這主要得益於技術創新、不斷累積的臨床證據以及不斷發展的供應生態系統。同位素生產技術的進步，包括新型迴旋加速器和發生器平台，提高了供應的可靠性，並實現了更廣泛的地理分佈。同時，靶向分子設計的突破，涵蓋單株抗體、胜肽和最佳化的小分子，拓展了可靶向的腫瘤類型，並改善了腫瘤與正常組織的比例。

對2025年關稅調整對放射性藥物相關人員的供應鏈經濟、生產決策和策略採購的影響進行務實分析

美國在2025年生效的關稅政策調整，對放射性核種藥物偶聯物的生產商、物流業者和臨床醫生而言，都構成重要的考量。進口關稅和歸類規則的調整將影響關鍵投入品的到岸成本，例如用於放射性標記和品管的同位素、前驅化學品和特殊耗材。同樣重要的是，活性藥物成分和醫用級組件的關稅待遇變化，其影響可能因供應鏈是垂直整合還是依賴跨境供應商而有所不同。

基於詳細細分市場的洞察，揭示了通路、交付方式、終端用戶環境、目標分子和適應症如何決定臨床和商業策略。

細分市場分析揭示了不同分銷管道、照射方式、最終用戶、目標分子和適應症所帶來的策略重點差異。不同管道的分銷運作要求各不相同：醫院藥房環境需要與患者照護流程和輻射安全基礎設施相整合；在線藥房管道側重於遠程物流和門診病人用藥的規範化配送；而零售藥房則側重於門診病人配藥流程和社區層面的宣傳活動。這些差異影響著商業性策略，並決定在培訓、基礎設施和夥伴關係方面的投資何時才能最為有效。

美洲、歐洲、中東和非洲以及亞太地區的區域基礎設施、監管差異和投資模式如何導致准入和部署策略的差異化

區域趨勢正在以不同的方式影響美洲、歐洲/中東/非洲和亞太地區開發商、製造商和供應商的戰略重點。在美洲，先進的臨床應用和高度集中的專業癌症治療中心為早期採用新型放射性核素療法創造了有利環境，而主要市場的監管和報銷框架則強調臨床療效和成本效益的證據。這種區域背景支持對集中式生產和分銷網路進行投資，以便服務於大都會圈的治療中心，並支援協調一致的臨床計畫。

決定哪些組織能夠在放射性藥物生態系統中成功實現規模化發展的，是其競爭角色、夥伴關係和營運能力。

放射性核種藥物偶聯物領域由眾多參與者主導，包括生物技術創新者、成熟的放射性藥物公司、專業契約製造機構和學術轉化研究中心。生物技術創新者透過新型靶點結構和First-in-Class的放射性組合來推動臨床差異化，而成熟的製造商則提供更廣泛的商業部署所需的規模、監管經驗和分銷網路。契約製造和服務供應商在實現快速生產、品管檢測和放射性物質處理方面發揮關鍵作用，從而加快新興開發商的臨床應用進程。

採取切實可行的策略措施，協調科學重點、供應鏈韌性和相關人員參與，以加速放射性藥物的負責任應用和商業性成功。

產業領導者應採取協作策略，整合科學差異化、切實可行的營運投資和相關人員參與。優先建構穩健的採購體系，為同位素和關鍵前驅物建立冗餘供應鏈，並探索區域生產夥伴關係，以降低跨境政策和關稅風險。同時，投資於能夠預見放射性藥物監管要求並隨著臨床需求成長而快速擴大生產規模的製造和品質系統。

我們採用透明的多學科研究途徑，結合臨床證據、技術檢驗、專家訪談和政策分析，以確保研究結果具有可操作性和可靠性。

本研究整合了同行評審的臨床文獻、監管指導文件、專利概況、公司資訊披露以及對臨床醫生、生產專業人員和供應鏈管理人員的專家訪談。證據基礎著重於機制理解、臨床試驗結果、營運案例研究和政策分析，以全面展現整個生態系統。研究結果盡可能透過多資訊來源進行三角驗證，以確保準確性並最大限度地減少偏差。

對技術進步、營運需求和夥伴關係重點的簡要總結，突顯了決定臨床療效能否轉化為患者廣泛應用的關鍵因素。

總之，放射性核種藥物偶聯物處於分子標靶治療和放射治療的策略性交會點，正從早期臨床檢驗走向更廣泛的臨床應用。同位素生產技術、標靶配體設計和輔助成像技術的進步正在降低關鍵的技術壁壘，而不斷湧現的臨床證據正促使醫療機構重組治療模式並增加對專業技術的投入。這些進展為能夠將科學創新與實際應用相結合的相關人員創造了重要的機會。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 放射性核種藥物複合物市場依釋放類型分類

  • 阿爾法發射體
  • BETA射線放射體

9. 以標靶分子分類的放射性核種藥物偶聯物市場

  • 單株抗體
  • 胜肽
  • 低分子化合物

第10章 依適應症分類的放射性核種藥物複合物市場

  • 神經內分泌腫瘤
  • 攝護腺癌

第11章 放射性核種藥物複合物市場（依分銷管道分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 放射性核種藥物複合物市場（依最終用戶分類）

  • 醫院
    • 大學醫院
    • 社區醫院
  • 研究所
  • 專科診所

13. 各地區放射性核種藥物複合物市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 放射性核種藥物複合物市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國放射性核種藥物複合物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章美國放射性核種藥物複合物市場

第17章：中國放射性核種藥物複合物市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Bayer AG
  • Curium Pharma SA
  • DongCheng Pharmaceutical Group
  • Eckert & Ziegler Strahlen-und Medizintechnik AG
  • Ion Beam Applications SA
  • Jubilant Pharmova Limited
  • Lantheus Holdings, Inc.
  • Nordion Inc.
  • Novartis AG
  • Point Biopharma Solutions, Inc.
  • Telix Pharmaceuticals Limited
Product Code: MRR-AE420CB1540D

The Radionuclide Drug Conjugate Market was valued at USD 840.27 million in 2025 and is projected to grow to USD 906.01 million in 2026, with a CAGR of 10.77%, reaching USD 1,720.27 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 840.27 million
Estimated Year [2026] USD 906.01 million
Forecast Year [2032] USD 1,720.27 million
CAGR (%) 10.77%

An authoritative primer describing the scientific basis, clinical promise, and operational prerequisites that define current radionuclide drug conjugate strategies

Radionuclide drug conjugates represent a convergence of targeted molecular therapy and radioactive payload delivery, designed to selectively deliver cytotoxic radiation to malignant tissues while sparing healthy structures. These agents pair a targeting ligand with a radioactive isotope, enabling clinicians to exploit molecular recognition to localize therapeutic radiation and, in some constructs, provide diagnostic imaging capability as part of a theranostic strategy. This dual utility enhances patient selection and treatment monitoring, which has elevated the clinical and commercial interest in these modalities.

The maturation of targeting molecules, improvements in isotope production, and refinements in linker chemistry have collectively reduced off-target toxicity and improved therapeutic indices. Parallel advances in imaging, dosimetry, and patient management protocols have strengthened clinical confidence, encouraging broader adoption within specialized oncology centers. Consequently, stakeholders across the value chain-including radiopharmaceutical developers, hospital systems, and specialty pharmacies-are re-evaluating infrastructure, logistics, and clinical pathways to integrate these agents responsibly.

As the technology moves from early clinical validation into more routine clinical practice, attention has shifted toward scalable manufacturing, safe distribution, and reproducible clinical workflows. At the same time, regulatory frameworks are evolving to address the unique safety and handling considerations for radiopharmaceuticals. Taken together, these dynamics create a strategic inflection point: organizations that align science, operations, and commercial execution now can capture early advantages in a field poised to influence several oncology treatment paradigms.

How technological breakthroughs, clinical validation, and evolving care models are reshaping the competitive and operational environment for radiopharmaceutical therapies

The landscape for radionuclide drug conjugates is undergoing transformative shifts driven by technological innovation, expanded clinical evidence, and evolving delivery ecosystems. Advances in isotope production technologies, including novel cyclotron and generator platforms, have improved supply reliability and enabled wider geographic distribution. At the same time, breakthroughs in targeting molecule design-spanning monoclonal antibodies, peptides, and optimized small molecules-have expanded the range of addressable tumor types and improved tumor-to-normal tissue ratios.

Clinically, increasing evidence for therapeutic benefit in indications such as prostate cancer and neuroendocrine tumors has moved radionuclide therapies beyond compassionate-use contexts into structured clinical pathways. This shift is encouraging multidisciplinary teams to create integrated care pathways that combine imaging specialists, nuclear medicine physicians, medical oncologists, and pharmacy operations. As a result, service models within hospitals and specialty clinics are adapting, with dedicated treatment suites, enhanced radiation-safety programs, and new pharmacist competencies.

Commercially, novel reimbursement discussions and value-based contracting experiments are reshaping how payers, providers, and manufacturers negotiate access. This development is accelerating partnerships across academia, biotech, and established radiopharmaceutical manufacturers to co-develop therapeutic and diagnostic pairings. Collectively, these technological, clinical, and commercial transitions are redefining competitive positioning and creating fresh opportunities for organizations that can execute across science, supply chain, and clinical implementation.

Practical analysis of how 2025 tariff adjustments will affect supply chain economics, manufacturing decisions, and strategic sourcing for radiopharmaceutical stakeholders

Tariff policy changes in the United States for 2025 introduce material considerations for manufacturers, logistics providers, and clinical implementers of radionuclide drug conjugates. Adjustments to import duties and classification rules influence the landed cost of key inputs such as isotopes, precursor chemicals, and specialized consumables used in radiolabeling and quality control. Equally important, changes to tariff treatment for active pharmaceutical ingredients and medical-grade components can create differential impacts depending on whether supply chains are vertically integrated or dependent on cross-border suppliers.

These tariff shifts increase the strategic importance of supply chain resilience and localization. Manufacturers and healthcare systems are responding by diversifying supplier portfolios, evaluating regional production options, and accelerating investment in domestic production capacity for critical isotopes and precursors. In practice, this means closer collaboration between radiopharmaceutical developers and regional cyclotron operators, as well as reconsideration of inventory strategies to balance cost, decay-related loss, and service reliability.

Moreover, tariff-driven cost pressures are likely to cascade into contract negotiations with payers and health systems, prompting a focus on demonstrable clinical value, optimized utilization, and efficiency in delivery models. For stakeholders, the policy environment underscores the need for proactive scenario planning, cross-functional alignment on sourcing decisions, and targeted capital allocation to mitigate tariff exposure while maintaining clinical continuity and patient access.

Detailed segmentation-driven insights that reveal how distribution channels, emission modalities, end-user settings, targeting scaffolds, and indications determine clinical and commercial strategy

Segmentation analysis reveals differentiated strategic priorities across distribution channels, emission types, end users, targeting molecules, and indications. Distribution by channel shows a divergence in operational requirements: hospital pharmacy settings require integration with inpatient care pathways and radiation-safety infrastructure, online pharmacy channels emphasize remote logistics and regulated shipping for outpatient dosing, while retail pharmacy involvement focuses on outpatient dispensing workflows and community-level education. These distinctions shape commercial approaches and influence where investment in training, infrastructure, and partnerships will be most effective.

Emission type drives product design and clinical application. Alpha-emitting constructs tend to offer high linear energy transfer with short tissue penetration, making them attractive for micrometastatic disease and targeted cell kill, whereas beta-emitting constructs provide longer-range radiation useful for bulky disease and cross-fire effects. Appreciating these differences informs clinical trial design, patient selection strategies, and the development of accompanying diagnostic tools to optimize therapeutic index.

End-user segmentation further refines go-to-market tactics. Hospitals, including academic centers and community hospitals, demand robust protocols for inpatient and outpatient administration and benefit from institutional research infrastructure. Research institutes prioritize investigational flexibility and translational science partnerships, while specialty clinics emphasize streamlined outpatient workflows and rapid patient throughput. Tailoring commercial interactions to these varied settings improves adoption and supports sustained clinical integration.

Targeting molecule selection-monoclonal antibody, peptide, or small molecule-affects pharmacokinetics, tumor penetration, and manufacturing complexity. Monoclonal antibodies often require sophisticated biomanufacturing and may deliver prolonged tumor exposure, peptides typically enable rapid tumor targeting with simpler chemistry, and small molecules can provide favorable tissue permeability with ease of synthesis. These molecular attributes intersect with indication-specific needs; for example, neuroendocrine tumor therapies frequently exploit peptide receptor targets, while prostate cancer strategies commonly use small molecules or antibody fragments tuned to prostate-specific antigens. Together, these segmentation insights guide prioritization of R&D, clinical development pathways, and commercial models.

How regional infrastructure, regulatory heterogeneity, and investment patterns across the Americas, Europe Middle East & Africa, and Asia-Pacific drive differentiated access and deployment strategies

Regional dynamics are shaping strategic priorities for developers, manufacturers, and providers in distinct ways across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, advanced clinical adoption and concentration of specialized oncology centers create a favorable environment for early implementation of novel radionuclide therapies, while regulatory and reimbursement frameworks in key markets emphasize evidence of clinical benefit and cost-effectiveness. This regional context supports coordinated clinical programs and investment in centralized production and distribution networks that can serve large metropolitan treatment centers.

By contrast, Europe, Middle East & Africa exhibits heterogeneous capabilities, with advanced nuclear medicine expertise concentrated in select European countries and varied regulatory and infrastructure readiness across the broader region. This heterogeneity necessitates differentiated market-access strategies and localized partnerships that align production and clinical training with regional capacity. Increasing collaboration across academic consortia and pan-regional initiatives is accelerating knowledge transfer and creating shared pathways for patient access.

In the Asia-Pacific region, rapid capacity building, investments in cyclotron infrastructure, and rising oncology care demand are creating a dynamic environment for radiopharmaceutical deployment. Several countries are expanding clinical trial activity and investing in domestic manufacturing to reduce dependency on imports. Consequently, stakeholders are prioritizing regionally tailored commercial models, local regulatory engagement, and scalable delivery solutions to meet both urban and decentralized care needs. Across all regions, cross-border collaboration on supply chain logistics and harmonization of safety standards remains a priority to ensure consistent patient access.

A synthesis of competitive roles, partnerships, and operational capabilities that determine which organizations will scale successfully in the radiopharmaceutical ecosystem

Competitive dynamics in the radionuclide drug conjugate space are shaped by players spanning biotech innovators, established radiopharmaceutical firms, specialized contract manufacturing organizations, and academic translational centers. Biotech innovators are driving clinical differentiation through novel targeting constructs and first-in-class emission combinations, while established manufacturers contribute scale, regulatory experience, and distribution networks necessary for broader commercial rollout. Contract manufacturing and service providers play a critical role in enabling agile production, quality-control testing, and handling of radioactive materials, thereby reducing time-to-clinic for emerging developers.

Academic and research institutions continue to be essential sources of discovery and translational expertise, frequently collaborating with industry partners to de-risk early clinical stages. Strategic alliances, licensing deals, and joint development agreements are common mechanisms for accelerating access to isotopes, targeting ligands, and complementary diagnostic assets. Additionally, an emerging cohort of logistics and specialty pharmacy providers is building capabilities in cold-chain management, just-in-time delivery, and on-site radiolabeling support, which are essential to operationalize therapies with short isotope half-lives.

Overall, competitive advantage accrues to organizations that can integrate scientific differentiation with reliable manufacturing, regulatory clarity, and nimble distribution. Firms that invest in multi-stakeholder partnerships and demonstrate operational excellence in handling radiopharmaceutical-specific challenges will be best positioned to scale adoption across clinical settings.

Actionable strategic moves that align scientific priorities, supply resilience, and stakeholder engagement to accelerate responsible adoption and commercial success in radiopharmaceuticals

Industry leaders should pursue a coordinated strategy that aligns scientific differentiation with pragmatic operational investments and stakeholder engagement. Prioritize resilient sourcing by establishing redundant supply lines for isotopes and critical precursors, while exploring regional production partnerships to mitigate cross-border policy and tariff exposures. Simultaneously, invest in manufacturing and quality systems that anticipate regulatory expectations for radiopharmaceuticals and enable rapid scale-up when clinical demand intensifies.

Operationally, strengthen clinical adoption by supporting end-user readiness: develop training programs for hospital pharmacy teams and nuclear medicine staff, design standardized administration protocols for academic and community hospitals, and create streamlined workflows for specialty clinics and research institutes. On the commercial front, engage proactively with payers and health technology assessment bodies to articulate clinical value propositions, support real-world evidence generation, and pilot reimbursement models that reflect total-cost-of-care benefits. Forge alliances with logistics and specialty pharmacy partners to ensure dependable distribution and to address the unique cold-chain and radioactive handling requirements.

Finally, align R&D priorities with segmentation realities: match targeting modalities to indication-specific biology, optimize emission selection based on disease burden and microenvironment, and design companion diagnostics to improve patient selection. By adopting an integrated approach that combines supply chain resilience, clinical operations, and payer engagement, organizations can accelerate responsible adoption and create sustainable pathways for growth.

Transparent and multidisciplinary research approach combining clinical evidence, technical validation, expert interviews, and policy analysis to ensure practical and reliable insights

This research synthesis integrates peer-reviewed clinical literature, regulatory guidance documents, patent landscapes, company disclosures, and primary expert interviews with clinicians, manufacturing specialists, and supply-chain managers. The evidence base emphasizes mechanistic understanding, clinical trial outcomes, operational case studies, and policy analyses to capture a holistic view of the ecosystem. Wherever possible, findings were triangulated across multiple information sources to ensure accuracy and minimize bias.

Qualitative inputs included structured interviews with practicing nuclear medicine physicians, hospital pharmacists, and cancer center administrators to understand real-world workflows and adoption barriers. Technical validation drew on manufacturing experts and radiochemistry specialists to assess production feasibility, handling constraints, and quality-control challenges. Policy analysis referenced recent regulatory guidance and tariff notifications to interpret implications for cross-border supply and local production strategies.

Analytical methods combined thematic synthesis of qualitative insights with scenario-based impact analysis to explore how operational, regulatory, and commercial variables interact. The methodology prioritized transparent assumptions and documented evidence pathways so that conclusions remain actionable for decision-makers seeking to align research priorities, capital allocation, and commercialization plans.

Concise synthesis of technological progress, operational imperatives, and partnership priorities that will determine whether clinical promise translates into broad patient access

In summary, radionuclide drug conjugates occupy a strategic intersection of molecular targeting and radiotherapy that is progressing from early clinical validation toward broader clinical integration. Progress in isotope production, targeting-ligand engineering, and supportive imaging approaches has reduced key technical barriers, while evolving clinical evidence is prompting healthcare providers to reconfigure delivery models and invest in specialized capabilities. These developments create meaningful opportunities for stakeholders that can align scientific innovation with operational readiness.

However, successful scale-up depends on solving practical challenges: establishing resilient supply chains, navigating changing tariff and regulatory landscapes, and ensuring end-user preparedness across hospitals, specialty clinics, and research institutes. Strategic partnerships among developers, manufacturers, logistics providers, and clinical centers will be essential to bridge gaps in capacity and expertise. Ultimately, organizations that combine durable technical differentiation with disciplined execution in manufacturing, distribution, and payer engagement will be best positioned to translate scientific promise into sustained clinical impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Radionuclide Drug Conjugate Market, by Emission Type

  • 8.1. Alpha Emitter
  • 8.2. Beta Emitter

9. Radionuclide Drug Conjugate Market, by Targeting Molecule

  • 9.1. Monoclonal Antibody
  • 9.2. Peptide
  • 9.3. Small Molecule

10. Radionuclide Drug Conjugate Market, by Indication

  • 10.1. Neuroendocrine Tumor
  • 10.2. Prostate Cancer

11. Radionuclide Drug Conjugate Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Radionuclide Drug Conjugate Market, by End User

  • 12.1. Hospital
    • 12.1.1. Academic Hospital
    • 12.1.2. Community Hospital
  • 12.2. Research Institute
  • 12.3. Specialty Clinic

13. Radionuclide Drug Conjugate Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Radionuclide Drug Conjugate Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Radionuclide Drug Conjugate Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Radionuclide Drug Conjugate Market

17. China Radionuclide Drug Conjugate Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Bayer AG
  • 18.6. Curium Pharma S.A.
  • 18.7. DongCheng Pharmaceutical Group
  • 18.8. Eckert & Ziegler Strahlen- und Medizintechnik AG
  • 18.9. Ion Beam Applications S.A.
  • 18.10. Jubilant Pharmova Limited
  • 18.11. Lantheus Holdings, Inc.
  • 18.12. Nordion Inc.
  • 18.13. Novartis AG
  • 18.14. Point Biopharma Solutions, Inc.
  • 18.15. Telix Pharmaceuticals Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY ALPHA EMITTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY ALPHA EMITTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY ALPHA EMITTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY BETA EMITTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY BETA EMITTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY BETA EMITTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY MONOCLONAL ANTIBODY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY MONOCLONAL ANTIBODY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY PEPTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY PEPTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY PEPTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY NEUROENDOCRINE TUMOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY NEUROENDOCRINE TUMOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY NEUROENDOCRINE TUMOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY ACADEMIC HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY ACADEMIC HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY ACADEMIC HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COMMUNITY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COMMUNITY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COMMUNITY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY RESEARCH INSTITUTE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY RESEARCH INSTITUTE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 118. GCC RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GCC RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. GCC RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 121. GCC RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 122. GCC RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. GCC RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. GCC RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 139. G7 RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. G7 RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. G7 RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 142. G7 RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 143. G7 RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. G7 RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. G7 RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 146. NATO RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. NATO RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. NATO RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 149. NATO RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 150. NATO RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. NATO RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. NATO RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED STATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED STATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 162. CHINA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. CHINA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 165. CHINA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. CHINA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)